126.16
1.93%
-2.48
After Hours:
125.00
-1.16
-0.92%
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk ADR stock is currently priced at $126.16, with a 24-hour trading volume of 3.08M.
It has seen a -1.93% decreased in the last 24 hours and a -2.02% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $127.9 pivot point. If it approaches the $125.5 support level, significant changes may occur.
Previous Close:
$128.64
Open:
$127.16
24h Volume:
3.08M
Market Cap:
$562.84B
Revenue:
$33.71B
Net Income/Loss:
$12.15B
P/E Ratio:
52.40
EPS:
2.4077
Net Cash Flow:
$10.16B
1W Performance:
+1.31%
1M Performance:
-2.02%
6M Performance:
+29.37%
1Y Performance:
-26.00%
Novo Nordisk ADR Stock (NVO) Company Profile
Name
Novo Nordisk ADR
Sector
Industry
Phone
45 44 44 88 88
Address
Novo Allé, Bagsvaerd
Novo Nordisk ADR Stock (NVO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
Jan-23-24 | Initiated | Morgan Stanley | Overweight |
Jan-16-24 | Resumed | UBS | Neutral |
Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
Oct-02-23 | Initiated | Argus | Buy |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jun-28-22 | Downgrade | UBS | Neutral → Sell |
Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
Jan-25-22 | Downgrade | Liberum | Hold → Sell |
Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
Jan-15-21 | Initiated | Deutsche Bank | Buy |
Sep-29-20 | Initiated | Berenberg | Hold |
Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
May-11-20 | Downgrade | UBS | Buy → Neutral |
May-04-20 | Initiated | Cowen | Market Perform |
Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
Dec-11-18 | Resumed | Jefferies | Hold |
Oct-09-18 | Initiated | Guggenheim | Buy |
Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk ADR Stock (NVO) Latest News
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why
Zacks Investment Research
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Zacks Investment Research
Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?
Zacks Investment Research
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight Loss Drug Market
The Motley Fool
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
The Motley Fool
Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?
Zacks Investment Research
Novo Nordisk ADR Stock (NVO) Financials Data
Novo Nordisk ADR (NVO) Revenue 2024
NVO reported a revenue (TTM) of $33.71 billion for the quarter ending December 31, 2023, a +34.71% rise year-over-year.
Novo Nordisk ADR (NVO) Net Income 2024
NVO net income (TTM) was $12.15 billion for the quarter ending December 31, 2023, a +54.40% increase year-over-year.
Novo Nordisk ADR (NVO) Cash Flow 2024
NVO recorded a free cash flow (TTM) of $10.16 billion for the quarter ending December 31, 2023, a +11.80% increase year-over-year.
Novo Nordisk ADR (NVO) Earnings per Share 2024
NVO earnings per share (TTM) was $2.7025 for the quarter ending December 31, 2023, a +56.07% growth year-over-year.
About Novo Nordisk ADR
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk A/S has a research and licensing agreement with DUKE National University Singapore Medical School to develop stem cell-based treatments for chronic heart failure and age-related macular degeneration; and a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S has a collaboration agreement with Embark Biotech ApS for the discovery of novel treatments for obesity and its associated metabolic pathologies. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Cap:
|
Volume (24h):